Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 21, 2025
Are the CTV-to-PTV margins currently used in online adaptive radiotherapy for prostate cancer too large? The impact of the distribution of microscopic disease on treatment margin requirementsMathijs G Dassen, Marcel van Herk, Marnix G Witte, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 22, 2023
Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: Implications for treatment marginsMathijs G Dassen, Tomas Janssen, Martijn Kusters, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 11, 2019
The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastasesMaarten L J Smits, Mathijs G Dassen, Jip F Prince, et al.
Practical Radiation Oncology|November 7, 2024
Simulation of Focal Boosting in Online Adaptive MRI-Guided SBRT for Patients With Locally Advanced Prostate Cancer With Seminal Vesicle InvolvementMathijs G Dassen, Ben Neijndorff, Anja Betgen, et al.
BMJ Open|May 7, 2026
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trialSian Cooper, Sophie Alexander, Dylan Breitkreutz, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2025
Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate CancerMathijs G Dassen, Alison C Tree, Lisa Wiersema, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 8, 2026
Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility studySian Cooper, Sophie Alexander, Charlotte Cherry, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 28, 2026
Automated prospective quality assurance of tumor segmentation and treatment planning in the hypo-FLAME 3.0 trialJoost Surewaard, Ruben Bosschaert, Herbert Beemster, et al.
Pageof 1